Skip to main content
    R

    Repare Therapeutics Inc (RPTX)

    Official site

    BIOTECHNOLOGY

    $2.65
    +0.00 (+0.00%)

    Last updated: Jan 28, 2026 at 4:00 PM ET

    Repare Therapeutics Inc (RPTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 14, 2025. Financial statements from company filings, amounts in US dollars.

    Repare Therapeutics reported revenue of $53.48M for the fiscal year ended Dec 31, 2024, up 4.6% from the year before. That year, net income was -$84.69M with a net margin of -158.4%, operating cash flow was -$76.44M and free cash flow was -$76.44M. The quarter ended Sep 30, 2025 had revenue of $11.62M and net income of $3.26M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$53.48M+4.6%100.0%-174.9%-158.4%
    Dec 2023$51.13M-61.2%100.0%-227.3%-183.4%
    Dec 2022$131.83M+1634.6%100.0%-15.0%-22.0%
    Dec 2021$7.60M+5529.6%100.0%-1429.7%-1406.7%
    Dec 2020$135.00KN/A100.0%-40223.7%-39568.1%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$53.48M$51.13M$131.83M$7.60M$135.00K$0$0$0
    Cost of revenue$0$0$0$0$0$0$407.00K$102.00K
    Gross profit$53.48M$51.13M$131.83M$7.60M$135.00K$0-$407.00K-$102.00K
    Research and development$115.94M$133.59M$119.07M$90.05M$40.09M$21.00M$9.91M$4.40M
    Operating income-$93.52M-$116.22M-$19.80M-$108.66M-$54.30M-$26.38M-$12.82M-$6.17M
    Net income-$84.69M-$93.80M-$29.05M-$106.91M-$53.42M-$27.22M-$14.28M-$7.80M
    EBITDAN/AN/A-$19.79M-$107.26M-$54.09MN/AN/AN/A
    Fiscal years ended Dec 2017 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$11.62M$250.00K$0-$53.48M$0$1.07M$52.40M$13.05M$2.16M$30.25M$5.68M$18.20M
    Gross profit$11.62M$250.00K$0-$454.00K$0$1.07M$52.40M$13.05M$2.16M$30.25M$5.68M$18.20M
    Operating income$1.13M-$17.78M-$31.19M-$30.65M-$36.37M-$37.32M$10.82M-$30.87M-$38.42M-$12.26M-$34.68M-$19.63M
    Net income$3.26M-$16.74M-$30.04M-$28.67M-$34.41M-$34.77M$13.16M-$28.03M-$18.88M-$11.95M-$34.94M-$31.66M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $1.84M by $82.87M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$176.51M$253.90M$364.07M$368.71M$357.09M$102.69M$13.93MN/A
    Current assets$171.15M$243.69M$353.98M$351.41M$346.55M$98.57M$12.05MN/A
    Cash and equivalents$84.72M$111.27M$159.52M$334.43M$326.18M$94.80M$10.73MN/A
    Total liabilities$25.38M$41.82M$84.56M$80.29M$70.26M$12.83M$36.31MN/A
    Short-term debt$1.84M$2.40M$2.17M$1.72M$697.00K$625.00KN/AN/A
    Shareholder equity$151.13M$212.08M$279.52M$288.42M$286.83M-$46.13M-$22.38MN/A
    Fiscal years ended Dec 2017 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$126.75M$130.49M$144.02M$176.51M$206.39M$235.34M$263.08M$253.90M$286.41M$301.59M$336.31M$364.07M
    Total liabilities$11.62M$20.09M$18.93M$25.38M$31.43M$31.67M$31.13M$41.82M$53.04M$56.17M$85.06M$84.56M
    Cash and equivalents$72.83M$67.66M$84.45M$84.72M$80.54M$79.82M$103.22M$111.27M$107.37M$115.54M$121.46M$159.52M
    Shareholder equity$115.13M$110.41M$125.10M$151.13M$174.96M$203.68M$231.95M$212.08M$233.37M$245.41M$251.24M$279.52M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$76.44M-$127.16M$322.00K-$85.80M-$6.08M-$18.43M-$12.62M-$6.01M
    Capital expenditures$0$1.94M$602.00K$1.69M$2.24M$1.30M$583.00K$1.16M
    Free cash flow-$76.44M-$129.10M-$280.00K-$87.49M-$8.32M-$19.73M-$13.20M-$7.16M
    Investing cash flow$49.47M$78.04M-$175.78M-$1.68M-$9.76M-$1.30M-$583.00K-$1.16M
    Financing cash flow$542.00K$842.00K$880.00K$95.56M$247.84M$103.24M$103.24M$30.46M
    Fiscal years ended Dec 2017 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow$2.65M-$16.34M-$29.13M-$27.32M-$30.54M-$30.51M$11.93M-$28.16M-$32.87M-$34.35M-$31.79M-$29.64M
    Capital expenditures$0$0$0$0$0$0$0$398.00K$0$1.06M$475.00K$1.72M
    Free cash flow$2.65M-$16.34M-$29.13M-$27.32M-$30.54M-$30.51M$11.93M-$28.55M-$32.87M-$35.41M-$32.26M-$31.36M
    Last 12 quarters

    Frequently Asked Questions About RPTX

    What is Repare Therapeutics' annual revenue?

    Repare Therapeutics reported revenue of $53.48M for the fiscal year ended Dec 31, 2024.

    How fast is Repare Therapeutics' revenue growing?

    Revenue was up 4.6% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 91.6%.

    Is Repare Therapeutics profitable?

    No. Repare Therapeutics reported net income of -$84.69M for the fiscal year ended Dec 31, 2024, with a net margin of -158.4%.

    How much free cash flow does RPTX generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$76.44M minus capital expenditures of $0 produced free cash flow of -$76.44M.

    How much debt does Repare Therapeutics have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $1.84M and cash and equivalents of $84.72M.